Oncology Franchise??? Really???

Quote
"Pay us more" what a douchebag! So you've been here less than a year and bragging about how much your paid and already complaining? We are all overpaid for what we do but it sounds like you take the cake! You must be a hoot at a party pretending to be a glorified physician because you can learn one drug! A seeing eye dog could do your job.
 




















Anonymous said:
What? The most? Listen here buddy, we run this now. I hope you enjoyed your reign, but Hep C is what makes the money now, enjoy the back seat.
Click to expand...

HCV makes the money now but don't forget where you came from. There would be no Gilead HCV without HIV. Period! Where do you think the $$$ to purchase PharmAsset was generated?
 












Anonymous said:
Listen here, in the next year we HCV will have equalled all of HIV in the last 5 years. We own you now....fall in line
Click to expand...

Listen clown! I said HCV is the money winner NOW, but you don't slap your mama and pappy cuz you're now a college graduate. They put your dumba$$ through college! Get it now genius? Hopefully, your HCV colleagues show a little more gratitude than you are showing.
 




Anonymous said:
Listen clown! I said HCV is the money winner NOW, but you don't slap your mama and pappy cuz you're now a college graduate. They put your dumba$$ through college! Get it now genius? Hopefully, your HCV colleagues show a little more gratitude than you are showing.
Click to expand...

You're old news, competition will knock you down and we'll be doing all HIV revenue combined in the next 2 years. You're 2nd class now, October is when we'll really show you who's boss. Thanks for the past, but we'll put up 30 billion in the next two years.
 




Are you kidding me ???? Don't we all work for the same company? Does it really matter? Please show some humility and realize that everyone has a role to play in the success (or failure) of this company.
 








Here's a way out of this mess

Xtandi field force gets a staffing boost for market-share battle with Zytiga
September 15, 2014 | By Tracy Staton

Astellas and Medivation bagged that new Xtandi approval in prostate cancer. What next? Gear up for a head-to-head with Johnson & Johnson's ($JNJ) Zytiga. And to do that, Medivation is expanding its sales force by 50%, Medical Marketing & Media reports.

With Astellas fielding 90 reps to tout Xtandi, Medivation decided to boost its team to 90 reps from 60. That's because the new label--backing Xtandi for use in patients not yet treated with chemo--opens up a new group of potential prescribers. Naturally, Medivation wants to reach them.

In a conference call about the new approval, CEO Dr. David Hung said Medivation and Astellas could previously only target urologists who deliver chemotherapy. That's only "a small segment" of the urology universe. Now that the approval nixes chemo as a prerequisite, the two partners can "target all urologists," Hung said (as quoted by MM&M).

Of course, Zytiga has a big head start in the pre-chemo setting, with that FDA nod under its belt since December 2012. But analysts give Xtandi a good shot at dominating the first-line market.

When Medivation unveiled its pre-chemo data early this year, JPMorgan analyst Geoffrey Meacham said the "impressive" stats "definitely favor the Astellas-Medivation drug." The data left "little room for debate on whether Xtandi or J&J's Zytiga will have majority market share" in that group of patients, he said.

Last week, as the FDA approval came through, the enthusiasm was undiminished. Leerink Partners' Howard Liang had already posited in an August note that Xtandi's success in the post-chemo world is a sign of things to come in pre-chemo patients.

But price could be a factor, as MM&M notes. Liang himself has said that some insurers have favored Zytiga because of the cost difference. (When Xtandi launched, it carried a $74,500 price tag, compared with Zytiga's $66,000.) For instance, in January, Blue Cross of Massachusetts put Xtandi behind Zytiga on a new step-therapy policy in prostate cancer. So, while the field reps knock on doors in urology and oncology, Astellas and Medivation will have to make their case with payers as well.

Still, there's plenty of room for both Xtandi and Zytiga to be blockbusters. Decision Resources has said that the prostate cancer market is expected to double to $9.1 billion by 2021, with Xtandi expected to hit $2.2 billion by then.
 












Anonymous said:
Yawn ......I've been here 10+ years. My eTrade account has more zeros than the revenue $s you bring in. Pay respect.
Click to expand...

I've been here 100+ years, my account has...sounds ridiculous? No way to check, but what you can check is what it'll feel like to be the second tier rep at our company when we announce at the meeting what we do for us and you'll be forced to clap for me as I walk across the stage, I'll wave to you while you're eating the banquet chicken.
 




Anonymous said:
I've been here 100+ years, my account has...sounds ridiculous? No way to check, but what you can check is what it'll feel like to be the second tier rep at our company when we announce at the meeting what we do for us and you'll be forced to clap for me as I walk across the stage, I'll wave to you while you're eating the banquet chicken.
Click to expand...

What I WILL check is my etrade account, and I'll do it as you walk across the stage. All the while I'll be planning my own trip with my own money. While you bask in your glory getting drunk on Bud Light I'll be planning a Hawaiian trip with your wife. Don't worry - out of respect for all that you do for the company I won't embarrass you. She'll say it's a girls' trip.
 




Anonymous said:
What I WILL check is my etrade account, and I'll do it as you walk across the stage. All the while I'll be planning my own trip with my own money. While you bask in your glory getting drunk on Bud Light I'll be planning a Hawaiian trip with your wife. Don't worry - out of respect for all that you do for the company I won't embarrass you. She'll say it's a girls' trip.
Click to expand...

Again, your etrade account is so good, right right. I'm sure it'll be a girls trip aren't All you boys in that division really ladies? Or are you still on the down low?

Bow to us.... You are nothing, you are in par with the cardio pulmonary.
 












Similar threads

Is Gilead expanding their oncology franchise?
Replies
2
Views
2K
Gilead Sciences
anonymous
Oncology MSL Layoffs
Replies
5
Views
1K
Gilead Sciences
anonymous
Oncology Account Director openings
Replies
14
Views
5K
Gilead Sciences
anonymous
More Oncology Assets Acquired by GILD
Replies
2
Views
2K
Gilead Sciences
anonymous
Oncology back stabbers are...
Replies
8
Views
5K
Gilead Sciences
anonymous
Top Bottom
Back
Quote